Sign in to fuzzto save your conversations, follow your research and come back anytime.
Artemis Medicare Services
SectorHealthcare
Company insights, generated from the most recent coverage.
The ~87% climb off the April 2026 low of ₹202.85 is a re-rating, not just earnings — the market repriced Artemis from a risky turnaround into a validated growth platform.
Shares changing hands at ~8% of equity in a single session alongside the rally points to genuine institutional accumulation, not retail momentum chasing.
Street is split on how much upside is left — InCred's ₹437 target sits ~26% above the ₹346.50 median of four covering analysts, so the bull case rests on hitting the FY28E EBITDA ramp rather than consensus numbers.
